Wellinks, a leader in cardiopulmonary care, today announced the first close of its Series B Funding, securing $10 million to fund commercial growth with participation from UMass Memorial Health and inside investors. The investment builds on Wellinks' multiyear relationship with UMass Memorial Health and other partners to accelerate the expansion of Wellinks' predictive care solution.

Wellinks is redefining how respiratory care is delivered. Our solution combines the benefits of virtual chronic care disease management with the power of remote patient monitoring through our proprietary, FDA-cleared technology. Our Health Tags offer passive, continuous monitoring that predicts clinical deterioration up to one week before a patient feels the onset of symptoms. By pairing predictive insights with proactive clinical intervention, Wellinks demonstrates results in reducing acute care utilization, readmission rates, and total cost of care. We are closing care gaps and changing the paradigm in how this traditionally underserved population receives care.